Predict your next investment

Venture Capital
FINANCIAL | Investment Firms & Funds
medicxi.com

See what CB Insights has to offer

Investments

106

Portfolio Exits

26

Funds

5

Partners & Customers

1

About Medicxi Ventures

Medicxi Ventures is a venture capital firm investing in life sciences, with a particular focus on therapeutics. The firm invests at the very early-stage of drug development, when candidate drugs have just been discovered and are entering preclinical stage, as well as at later stages of clinical development.

Medicxi Ventures Headquarter Location

25 Great Pulteney Street

London, England, W1F 9LT,

United Kingdom

+44 20 7952 1788

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Medicxi Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Medicxi Ventures in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Medicxi Ventures Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Medicxi Ventures Rank

Latest Medicxi Ventures News

After its First Success, the Virtual Biotech Team is Back at it Again

Nov 19, 2020

SuperX has raised €10.3M ($11M) in Series A from Medicxi and J&J Innovation to develop anticoagulant antibodies for stroke and heart attacks. The team behind XO1, which was acquired by J&J’s Janssen back in 2015, is repeating the whole process again. Their new company, SuperX, is also focused on the discovery of anticoagulant antibodies to treat stroke and heart attack without inducing bleeding. It has even raised €10.3M ($11M) in Series A, the same amount XO1 raised back in 2013. As well as XO1, SuperX is a virtual biotech. This means that the company, based in the Babraham Research Campus south of Cambridge, will have no internal operations. Instead, it will outsource drug discovery and development to providers, most of them located on the same campus. ADVERTISEMENT But let me introduce you to the team first. XO1 co-founders David Grainger, Jim Huntington and Trevor Baglin are now CEO, CSO and CMO of SuperX, respectively. Jo Davies gets the role of IP manager again, while Bob Schroff takes on as operations chief. David Grainger (left), Jim Huntington (center) and Trevor Baglin (right) The specific target SuperX is behind is still unknown, but the team has revealed that it’s inspired from unusual patient cases, which was what led to the inception of XO1 too. In that case, a patient that reported symptoms of hemophilia turned out to stop bleeding naturally. Researchers identified the antibody responsible for it and developed an anticoagulant for stroke and heart attack that, unlike all of those in the market, doesn’t induce bleeding. SuperX is an asset-centric company, focusing solely on the development of antibodies against a certain drug target that is still undisclosed. Medicxi, which led the financing round, specializes in this business model. It allows the company to use limited resources with the single aim of transforming a molecule into an asset that bigger companies will be interested in acquiring. That’s exactly what happened with XO1, which was acquired by Janssen just 2 years after the company was founded. If everything goes well, SuperX could follow the same steps. J&J will keep its eyes on it as an investor through J&J Innovation. Images from YuriiHrb /Shutterstock, Medicxi Ventures, Jim Huntington /Twitter, Southern Hemophilia Network Support good journalism, subscribe to Labiotech Insider If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

Medicxi Ventures Investments

106 Investments

Medicxi Ventures has made 106 investments. Their latest investment was in Xenikos as part of their Convertible Note on September 9, 2021.

CBI Logo

Medicxi Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/8/2021

Convertible Note

Xenikos

$47.27M

No

2

8/31/2021

Series A

Versanis Bio

$70M

Yes

8

8/10/2021

Series B

Sydnexis

$45M

Yes

3

7/20/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

6/10/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/8/2021

8/31/2021

8/10/2021

7/20/2021

6/10/2021

Round

Convertible Note

Series A

Series B

Series A

Series A

Company

Xenikos

Versanis Bio

Sydnexis

Subscribe to see more

Subscribe to see more

Amount

$47.27M

$70M

$45M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

8

3

10

10

Medicxi Ventures Portfolio Exits

26 Portfolio Exits

Medicxi Ventures has 26 portfolio exits. Their latest portfolio exit was Orexia on February 16, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/16/2021

Merger

3

8/7/2020

IPO

$991

5

8/6/2020

IPO

$991

5

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

2/16/2021

8/7/2020

8/6/2020

00/00/0000

00/00/0000

Exit

Merger

IPO

IPO

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

5

5

10

10

Medicxi Ventures Acquisitions

1 Acquisition

Medicxi Ventures acquired 1 company. Their latest acquisition was Centessa Pharmaceuticals on .

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

Series A

$250M

Spinoff / Spinout

Date

Investment Stage

Series A

Companies

Valuation

Total Funding

$250M

Note

Spinoff / Spinout

Sources

Medicxi Ventures Fund History

5 Fund Histories

Medicxi Ventures has 5 funds, including Medicxi BioTech Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

9/22/2020

Medicxi BioTech Fund

$234.62M

1

9/18/2020

Medicxi Secondary I

Subscribe to see more

$99M

10

7/10/2019

Medicxi III

Subscribe to see more

$99M

10

6/14/2017

Medicxi Growth I

Subscribe to see more

$99M

10

4/19/2016

Medicxi Ventures I

Subscribe to see more

$99M

10

Closing Date

9/22/2020

9/18/2020

7/10/2019

6/14/2017

4/19/2016

Fund

Medicxi BioTech Fund

Medicxi Secondary I

Medicxi III

Medicxi Growth I

Medicxi Ventures I

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Amount

$234.62M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

Medicxi Ventures Partners & Customers

1 Partners and customers

Medicxi Ventures has 1 strategic partners and customers. Medicxi Ventures recently partnered with Domain Therapeutics on October 10, 2016.

Date

Type

Business Partner

Country

News Snippet

Sources

10/19/2016

Partner

Domain Therapeutics

France

1

Date

10/19/2016

Type

Partner

Business Partner

Domain Therapeutics

Country

France

News Snippet

Sources

1

Medicxi Ventures Team

3 Team Members

Medicxi Ventures has 3 team members, including current General Partner, Kevin Johnson.

Name

Work History

Title

Status

David Grainger

Founder

Current

Kevin Johnson

Founder

Current

Kevin Johnson

General Partner

Current

Name

David Grainger

Kevin Johnson

Kevin Johnson

Work History

Title

Founder

Founder

General Partner

Status

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.